Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"Janssen, JANSSEN NZ LIMITED",Ibrutinib,Relapsed or refractory mantle cell lymphoma (R/R MCL),Ibrutinib (Imbruvica),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
